Complement Regulation to Undo Systemic Harm in Preeclampsia

Pregnancy Related Clinical Trial

— CRUSH  

Official title:

Complement Regulation to Undo Systemic Harm in Preeclampsia: The CRUSH Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04725812
• Other study ID #: STUDY00000039
• Status: Terminated
• Phase: Phase 2
• Start date: September 13, 2021
• Est. completion date: December 7, 2021

Study information

• Verified date: November 2023
• Source: Cedars-Sinai Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase II, single arm, open-label study to determine if treatment with eculizumab prolongs pregnancy compared to historical controls in women with preeclampsia between 23-30 weeks gestation.

Description:

The purpose of this study is to determine if eculizumab is an effective treatment to prolong pregnancy in women with preeclampsia, compared to a historical control group of women that received standard of care alone. Eligible subjects will be women with preeclampsia before 30 weeks gestation, who have been deemed suitable for prolongation of pregnancy. The primary research procedure is administration of the study drug, eculizumab, by intravenous infusions weekly for four weeks, then every other week. Eculizumab is approved by the FDA for the treatment of women with atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria and is frequently used in pregnant women with these disorders. However, eculizumab is considered investigational in this study because it has not been approved by the FDA for use in patients with preeclampsia. Subject participation will last approximately 8-12 weeks on average, and the study drug will be continued until 48 hours after delivery in the treatment arm. All subjects will be followed at 2 weeks and 6 weeks after delivery to assess maternal and neonatal outcomes. A later visit may be required to complete the meningococcal vaccine schedule. The investigators believe that eculizumab will prolong pregnancy in women with preeclampsia diagnosed before 30 weeks gestation with overactive complement. As there is no effective treatment for preeclampsia other than delivery currently, women with preeclampsia before 30 weeks gestation are managed using a "watch and wait" approach (i.e., expectant management). Due to the unpredictable nature of preeclampsia, expectant management places mother and child at significant risk until delivery occurs. Eculizumab may be an improvement over current standard of care as it provides a treatment option for patients who would otherwise be managed with expectant management alone. If the study aims are achieved, eculizumab will emerge as an effective treatment option for women with preeclampsia.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: December 7, 2021
• Est. primary completion date: December 7, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 13 Years and older

Eligibility

Inclusion criteria:

1. Provision of signed and dated informed consent form

2. Stated willingness to comply with all study procedures & availability for study duration

3. Biologically female, aged =13, body weight =40kg

4. Diagnosed with preeclampsia between 23-29+6/7 weeks gestation, by following criteria:

1. Blood pressure =160 mmHg systolic or =110 mmHg diastolic OR

2. Blood pressure =140 mmHg systolic or =90 mmHg diastolic and at least one of the following i. Proteinuria (spot protein/creatinine =0.3mg/mg or 24Hr protein =300 mg) ii. Platelet count <100,000/µl iii. Aspartate or alanine transaminase >2x upper limit of normal iv. Creatinine >1.1 mg/dl or oliguria v. Pulmonary edema

5. Ability to take intravenous medication and be willing to adhere to the eculizumab regimen

6. Ability to receive meningococcal vaccine and be willing to adhere to antibiotic regimen Exclusion Criteria: An individual who meets any of the following criteria prior to enrollment will be excluded

from participation in this study:

1. Known allergic reactions eculizumab or meningococcal vaccine

2. Febrile illness within prior 2 weeks

3. Treatment with another investigational drug within previous 6 months

4. Inpatient expectant management for preeclampsia >72 hours prior to enrollment

5. Fetal contraindication to expectant management of pregnancy

6. Platelet count <50,000/µl

7. Diagnosis of hemolysis, elevated liver enzymes, low platelet count (HELLP) syndrome

• Must meet all of the following criteria to be excluded: LDH >600 U/L, platelet count < 100,000/µl, AST >2x upper limit of normal, ALT >2x upper limit of normal

8. Diagnosis of Eclampsia

9. Diagnosis of Placental abruption

10. Intrauterine fetal demise

11. Coagulopathy (INR = 1.5)

12. Fibrinogen <200 mg/dl

13. Persistent, severe headache unresponsive to medications

14. Persistent, severe visual disturbances

15. Persistent, severe epigastric or RUQ pain unresponsive to medications

16. Diagnosis of Systemic lupus erythematosus

17. Diagnosis of Anti-phospholipid antibody syndrome

18. Diagnosis of Atypical hemolytic uremic syndrome

19. Diagnosis of Paroxysmal nocturnal hemoglobinuria

20. Known complement deficiency

21. Diagnosis of Venous thromboembolism active or within 6 months of enrollment

22. Diagnosis of Human immunodeficiency virus (HIV)

23. Diagnosis of Hepatitis C virus (active viremia)

24. Diagnosis of Cancer (not in remission)

25. History of Solid organ transplant

26. Systemic viral or bacterial infection (active, untreated)

27. Active use of eculizumab at time of enrollment

28. Contraindication to eculizumab treatment or complement system blockade

29. Contraindication to meningococcal vaccine

30. Body weight <40kg

31. Age <13

32. Neutropenia (<1500/mm3)

33. Gonorrhea, chlamydia, or syphilis in current pregnancy

34. Illicit substance use in current pregnancy

35. Currently homeless or incarcerated

36. Alcoholism

37. Liver cirrhosis

38. Insulin dependent diabetes

39. Active use of immunosuppressive therapies, other than use of corticosteroids for fetal lung maturity

40. Use of prophylactic or therapeutic heparin, or low molecular weight heparin, in pregnancy for hypercoagulable condition

Related Conditions & MeSH terms

• AHUS
• Complement Abnormality
• Complement Regulatory Factor Defect
• Eculizumab
• HELLP
• HELLP Syndrome
• HELLP Syndrome Second Trimester
• HELLP Syndrome Third Trimester
• PNH
• Pre-Eclampsia
• Preeclampsia
• Pregnancy Related
• Severe Preeclampsia
• Syndrome

Intervention

Drug:
• Eculizumab
Eculizumab Intravenous Solution

Locations

Country	Name	City	State
United States	Cedars-Sinai Medical Center	Los Angeles	California

Sponsors (2)

Lead Sponsor	Collaborator
Cedars-Sinai Medical Center	Alexion Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Latency (in Days) From Enrollment to Delivery	The difference in mean number of days (latency) from enrollment in the study (or hospital admission for controls) to delivery between participant receiving eculizumab compared to historical controls.; For treatment-arm participants latency is determined from enrollment to delivery.; For historical controls latency is determined from hospital admission (or initial diagnosis for controls hospitalized for other indication) for preeclampsia until delivery.; Subjects and historical controls all defined as women with preeclampsia between 23-30 weeks gestation.	24 months
Secondary	Composite Adverse Maternal Outcomes	The difference in the composite number of adverse maternal outcomes between subjects receiving eculizumab compared to historical controls; •Adverse maternal outcomes directly attributed to preeclampsia defined as the following: syndrome of hemolysis, elevated liver enzyme, and low platelet count (HELLP), eclampsia, placental abruption, stroke, venous thrombosis or pulmonary embolism, pulmonary edema, posterior reversible encephalopathy syndrome, postpartum hemorrhage (>1000 cc), blood transfusion, admission to the intensive care unit, acute kidney injury, acute tubular necrosis, dialysis, or death	24 months
Secondary	Composite Adverse Neonatal Outcomes	The difference in the composite number of adverse neonatal outcomes between subjects receiving eculizumab compared to historical controls.; •Adverse neonatal outcomes directly attributable to preeclampsia or indirectly attributable due to preterm delivery due to preeclampsia defined as the following: Respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular hemorrhage, retinopathy of prematurity, necrotizing enterocolitis, seizure, hypoxic-ischemic encephalopathy, metabolic acidosis, infection, sepsis, previously unrecognized major malformation detected at birth, patent ductus arteriosus requiring indomethacin, or death.	24 months
Secondary	Changes in Blood and Urine Concentrations of Terminal Complement Protein C5a Before and After Each Treatment.	The Difference in the concentration of C5a in blood and urine, before treatment ( ex. visit day 1) compared to after treatment in each participant receiving eculizumab.; •Concentrations of C5a in blood and urine will be determined by enzyme linked immunosorbent assays (ELISA).	24 months
Secondary	Changes in Blood and Urine Concentrations of Terminal Complement Protein C5b-9 Before and After Each Treatment.	The difference in blood and urine concentrations of C5b-9, before treatment ( ex. visit day 1) compared to after treatment in each participant receiving eculizumab.	24 months
Secondary	Changes in Blood and Urine Concentrations of Complement Protein CD59 Before and After Each Treatment.	The difference in blood and urine concentrations of CD59, before treatment ( ex. visit day 1) compared to after treatment in each participant receiving eculizumab.	24 months
Secondary	Aspartate and Alanine Transaminase Concentration Before and After Each Treatment.	Differences in the concentration of aspartate and alanine transaminase (U/L) will be compared before treatment (ex. visit day 1) and after treatment in each participant receiving eculizumab.	24 months
Secondary	Hemoglobin Concentration Before and After Each Treatment.	Differences in the concentrations of measures of hemoglobin will be compared before treatment (ex. visit day 1) and after treatment in each participant receiving eculizumab.	24 months
Secondary	Platelet Count Before and After Each Treatment.	Differences in the platelet count will be compared before treatment (ex. visit day 1) and after treatment in each participant receiving eculizumab.	24 months
Secondary	Lactate Dehydrogenase Concentration Before and After Each Treatment.	Differences in the concentration of serum lactate dehydrogenase will be compared before treatment (ex. visit day 1) and after treatment in each participant receiving eculizumab.	24 months
Secondary	Serum Creatinine Before and After Each Treatment.	Differences in the concentration of serum creatinine will be compared before treatment (ex. visit day 1) and after treatment in each participant receiving eculizumab.	24 months
Secondary	Urine Protein Concentration Before and After Each Treatment.	Differences in urine protein concentration will be compared before treatment (ex. visit day 1) and after treatment in each participant receiving eculizumab.	24 months
Secondary	Ratio of Urine Protein to Urine Creatinine Before and After Each Treatment.	Differences in the ratio of urine protein concentration to urine creatinine concentration will be compared before treatment (ex. visit day 1) and after treatment in each participant receiving eculizumab.	24 months
Secondary	Serum Concentration of Soluble Fms-like Tyrosine Kinase 1 (sFlt-1) Before and After Each Treatment.	Differences in the concentration of soluble fms-like tyrosine kinase 1 (sFlt-1) will be compared before treatment (ex. visit day 1) and after treatment in each participant receiving eculizumab.	24 months
Secondary	Serum Concentration of Placental Growth Factor (PlGF) Before and After Each Treatment.	Differences in the concentration of placental growth factor (PlGF) will be compared before treatment (ex. visit day 1) and after treatment in each participant receiving eculizumab.	24 months
Secondary	Serum Ratio of Soluble Fms-like Tyrosine Kinase 1 (sFlt-1) Concentration to Placental Growth Factor (PlGF) Concentration (sFlt-1/PlGF) Before and After Each Treatment.	Differences in the serum ratio of soluble fms-like tyrosine kinase 1 (sFlt-1) concentration to placental growth factor (PlGF) concentration (sFlt-1/PlGF) will be compared before treatment (ex. visit day 1) and after treatment in each participant receiving eculizumab.	24 months
Secondary	Serious Adverse Events	Assessment of serious adverse events in eculizumab treatment arm compared with historical controls.; Neisseria meningitidis infection or development of invasive meningococcal disease, Neisseria gonorrhoeae, Neisseria sicca/subflava, and Neisseria spp unspecified and Aspergillus infections.; Graded clinical and laboratory abnormalities, according to the U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS; DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. [July 2017].	24 months